NORTH CHICAGO, Ill., June 2, 2026
AbbVie has announced that the European Commission (EC) has approved AQUIPTA® (atogepant) for the acute treatment of migraine in adults, marking a significant expansion of the company’s neuroscience portfolio and providing a new treatment option for millions of people living with this debilitating neurological condition across Europe. The approval allows AQUIPTA to be used on an as-needed basis for the treatment of migraine attacks with or without aura and complements its existing European indication as a preventive therapy for adults experiencing at least four migraine days per month. The decision was supported by positive findings from the pivotal Phase 3 ECLIPSE trial, which demonstrated rapid and sustained relief from migraine symptoms while maintaining a favorable safety profile. With this latest regulatory milestone, AQUIPTA becomes one of the few therapies in Europe approved for both the acute and preventive treatment of migraine, strengthening AbbVie’s position in the growing migraine therapeutics market and addressing a significant unmet medical need among patients seeking effective, fast-acting treatment options.
Phase 3 ECLIPSE Trial Demonstrates Rapid and Lasting Relief
The European Commission approval is based on robust clinical evidence generated from the Phase 3 ECLIPSE study, a multicenter, randomized, double-blind, placebo-controlled trial involving 1,328 adult migraine patients across multiple countries. The study successfully met its primary endpoint, showing that AQUIPTA achieved statistically significant pain freedom two hours after treatment compared with placebo during the first migraine attack. In addition, the therapy demonstrated superiority across several important secondary endpoints, including freedom from the most bothersome migraine symptom, meaningful pain relief within two hours, reduced need for rescue medication, and sustained pain freedom from 2 to 48 hours after dosing.
Researchers also reported consistent effectiveness across multiple migraine attacks, highlighting the therapy’s reliability in real-world treatment settings. These findings reinforce AQUIPTA’s potential to provide rapid symptom control while delivering long-lasting benefits for patients who often experience significant disruptions to daily activities, productivity, and quality of life due to recurring migraine episodes.
Expanding Treatment Options for a Global Health Burden
Advertisement
Migraine remains one of the world’s most prevalent neurological disorders, affecting approximately 14% of the global population and representing a leading cause of disability, particularly among working-age adults and women. Migraine attacks are frequently associated with severe headaches, nausea, sensitivity to light and sound, cognitive impairment, and functional limitations that can significantly affect both personal and professional life. In Europe alone, migraine contributes to substantial healthcare costs and productivity losses, creating a major socioeconomic burden.
AQUIPTA belongs to the class of calcitonin gene-related peptide (CGRP) receptor antagonists, commonly known as gepants, which specifically target a key biological pathway involved in migraine pathophysiology. Unlike traditional migraine medications that may be associated with cardiovascular limitations or medication-overuse concerns, CGRP-targeted therapies provide a more focused mechanism of action. The new approval expands access to innovative migraine care and offers clinicians additional flexibility when tailoring treatment strategies to individual patient needs.
AbbVie Strengthens Leadership in Migraine Innovation
The approval further reinforces AbbVie’s commitment to advancing therapies that address the full spectrum of migraine disease. By offering AQUIPTA as both an acute and preventive treatment option, the company is positioning itself as a leader in comprehensive migraine management. The dual-indication approval provides healthcare providers with greater therapeutic flexibility while enabling patients to access a treatment platform that can address both immediate symptom relief and long-term disease prevention.
Clinical data indicate that AQUIPTA’s safety profile remains generally consistent with previous studies, with the most commonly reported adverse events including nasopharyngitis and upper respiratory tract infections. As migraine treatment continues to evolve toward precision-targeted therapies, the availability of effective oral CGRP receptor antagonists represents an important advancement in neurological care. AbbVie’s latest regulatory success highlights ongoing innovation in neuroscience and reflects growing efforts to improve outcomes for patients affected by one of the most disabling neurological disorders worldwide.
Source: AbbVie press release
